Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with ...
News Medical on MSN9d
SAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142
SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...
Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study
MALMÖ, SWEDEN / ACCESS Newswire / February 7, 2025 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE) today published its Q4 and Full Year Report for 2024 (January - December), which is ...
Nasdaq1mon
Xenon Pharmaceuticals Outlines Clinical Milestones and Pipeline Progress for 2025, Including Phase 3 Studies for Azetukalner
The company anticipates topline data from its first Phase 3 study of azetukalner ... potassium channel modulator in late-stage clinical development for multiple indications. For more information ...
Business Wire1mon
Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis
Additionally, key exploratory efficacy endpoints showed promising activity of SOR102 across multiple clinical endpoints ... to advance SOR102 into Phase 2 development.” The randomized, double ...
Business Wire1mon
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung ...
“We are extremely pleased with these results of our Phase 2b clinical ... OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization ...